Keywords: NICE, Roche, bowel cancer, Avastin, bevacizumab
NICE rejects Roche’s bowel cancer drug Avastin for a second time
Article | 27 November 2009
Having given it the cold shoulder three years ago, Britain’s healthcare cost effectiveness watchdog , the National Institute for Health and Clinical Excellence (NICE) has again rejected Roche’s Avastin (also known as bevacizumab). NICE has appraised a total of 79 cancer drugs, of which 75% have been recommended for use.
NICE’s preliminary ruling on Avastin says the bowel cancer drug is too expensive to be used on the NHS. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
